Melanie DuBois

Nessuna posizione attualmente

Health Technology

Consumer Services

Profilo

Melanie DuBois worked as a Director of Quality Assurance at YM BioSciences, Inc. and as a Manager of Quality Assurance at GlaxoSmithKline Pharmaceuticals SA (Belgium).
She received an undergraduate degree from Toronto Metropolitan University in 1987.

Precedenti posizioni note di Melanie DuBois

Società	Posizione	Fine
GlaxoSmithKline Pharmaceuticals SA (Belgium) GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium.	Corporate Officer/Principal	01/01/2006
YM BioSciences, Inc. YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Melanie DuBois

Formazione di Melanie DuBois

Toronto Metropolitan University of

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Melanie DuBois

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
YM BioSciences, Inc. YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.	Health Technology
GlaxoSmithKline Pharmaceuticals SA (Belgium) GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium.	Health Technology